Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$4.51 USD

4.51
3,247,173

+0.42 (10.27%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $4.45 -0.06 (-1.33%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session

NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.

    Alexion Soliris Fails in Phase II/III Delayed Graft Function Study

    Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.

      Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

      Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

        Celgene (CELG) Otezla Approved in Japan for Two Indications

        Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

          Roche Presents Positive Follicular Lymphoma Data on Gazvya

          Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

            Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

            Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

              Indradip Ghosh headshot

              New Strong Buy Stocks for December 5th

              Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                Aimmune Closes Enrolment in Phase III Peanut Allergy Study

                Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101

                  Foamix Completes Enrolment in Phase III Acne Drug Studies

                  Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies

                    Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor

                    Valeant Pharmaceuticals International, Inc. (VRX) announced that it is expanding its sales force to reach primary care physicians.

                      Indradip Ghosh headshot

                      New Strong Buy Stocks for November 21st

                      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday